Phase 1, First-in-human, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses of XEN1101 and Preliminary Open-label Pharmacodynamic Assessment in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs XEN 1101 (Primary)
- Indications Epilepsy
- Focus Adverse reactions; First in man
- Sponsors Xenon Pharmaceuticals
- 17 Oct 2017 According to a Xenon Pharmaceuticals media release, the first subject has been dosed in this trial.
- 17 Oct 2017 Status changed from planning to recruiting, according to a Xenon Pharmaceuticals media release.
- 28 Apr 2017 New trial record